Hepion Pharmaceuticals (NASDAQ:HEPA) Trading Down 7.2% – Should You Sell?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares dropped 7.2% on Monday . The stock traded as low as $0.73 and last traded at $0.74. Approximately 2,468,358 shares traded hands during mid-day trading, an increase of 966% from the average daily volume of 231,637 shares. The stock had previously closed at $0.80.

Hepion Pharmaceuticals Price Performance

The firm has a market capitalization of $103,138.00, a PE ratio of -0.17 and a beta of 1.62. The company’s fifty day simple moving average is $8.33 and its 200 day simple moving average is $23.30.

Institutional Trading of Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP bought a new stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals at the end of the most recent reporting period. 17.24% of the stock is currently owned by institutional investors.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.